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Introduction 
Les premières applications cliniques de la thérapie photodynamique (PDT) remontent à plus d'une 
vingtaine d'années. Basée sur l'activation d'un médicament photosensibilisateur par une source 
lumineuse à une longueur d'onde spécifique, la PDT permet la destruction sélective de tissus 
contenant le produit actif. 
Ce procédé a été expérimenté dans le traitement de cancers en raison de la propriété du médicament à 
se concentrer dans les tumeurs tout en épargnant les structures normales contigües. Cependant, les 
photosensibilisateurs utilisés jusqu'à ce jour n'ont pas démontré une accumulation exclusive dans les 
tissus néoplasiques mais également dans les structures saines avoisinantes induisant une destruction 
tissulaire non sélective. Notamment, d'importantes complications ont été rapportées suite à 
l'utilisation de la PDT dans la cavité thoracique après la résection de mésothéliomes pleuraux, et ce 
malgré l'arrivée de photosensibilisateurs de secondes générations. 
De ce fait, plusieurs études expérimentales ont été menées afin d'améliorer la sélectivité tumorale du 
médicament en modulant différentes conditions de traitement et en modifiant la structure du photo-
sensibilisateur par pégylation. 
Le but de cette étude expérimentale est de corréler l'activité photodynamique, la phototoxicité et la 
distribution du m-tetrahydroxyphenylchlorin (mTHPC) et de sa forme pégylée, le PEG-mTHPC. 
De ce fait, un modèle de souris nues porteur de xenogreffes de mésothéliome humain a été utilisé pour 
étudier les deux photosensibilisateurs. 
De récents travaux avec ce modèle ont montré que la mesure de la concentration tissulaire du mTHPC 
et de sa forme pégylée par HPLC restait limitée afin de prédire l'activité photodynamique. De ce fait, 
nous pensons que les mesures de fluorescence peuvent être plus appropriée. Le signalement 
fluorescent est mesuré dans le tissu tumoral et dans une région contrôle de la peau afin d'étudier la 
distribution et l'intensité des deux sensibilisateurs. 
Méthode 
Des souris nues (cdlnu/nu mice) de 8 semaines ont été transplantées avec des fragments de 
mésothéliome malin humain ( H-meso-1). Ces derniers ont été obtenus à partir d'une suspension 
cellulaire. Au moins trois passages ont été faits dans les animaux, avant que le traitement soit initié. 
Deux groupes de 6 souris chacun ont été utilisés pour l'injection intraveineuse par la queue du 
mTHPC à 0.15 mg/kg et du PEG-mTHPC à dose équimolaire. Après trois jour, la tumeur ainsi qu'une 
région contrôle de la cuisse ont été illuminées sur une surface d'un diamètre de 1.2 cm et pendant 133 
secondes avec un laser à une longueur d'onde à 652 nm (fluence 20 J/cm2, fluence rate 150 mW/cm2). 
Les animaux ont été ensuite sacrifiés 72 heures après l'illumination. L'étendue de la nécrose tumorale 
et de la région contrôle ont été déterminées en aveugle par histomorphometrie par un pathologue 
(HJA). 
La fluorescence microscopique a été évaluée dans 12 souris à une concentration de 0 .15 et 0. 5 mg/kg 
pour le mTHPC, et à doses équimolaires pour le PEG-mTHPC. Trois animaux ont été injectés avec le 
mTHPC à 0.15 mg/kg, 3 autres à dose équimolaire avec la forme pégylée et 6 souris avec le mTHPC à 
0.5 mg/kg et à dose équimolaire. 
Les animaux ont été sacrifiés 72 heures après injection. L'intensité fluorescente des sensibilisateurs a 
été mesurée dans la tumeur et la région contrôle. 
Suite à cela, les coupes ont été fixées par H&E et superposées aux images fluorescentes, afin de 
localiser la distribution des deux photosensibilisateurs dans les différents compartiments tissulaires. 
Six souris transplantées n'ayant ni été injectées avec les sensibilisateurs ou illuminées ont servi de 
groupe contrôle. 
Résultats 
Trois jours après l'illumination, la PDT provoque une nécrose tumorale de 10 ± 5.4 mm2 pour le 
mTHPC à 0.15mg/kg et 5.2 ± 4.6 mm2 pour sa forme pégylée à dose équimolaire. Cependant, la 
nécrose tumorale induite par les deux formulations du sensibilisateur est significativement plus élevée 
que dans le groupe contrôle (0.33 ± 0.58 mm2) (P=0.02). Toutefois, le mTHPC pégylé provoque une 
photosensibilité cutanée moins importante que la forme non-pegylée. Dans les deux groupes, aucune 
nécrose n'a été observé dans la cuisse des animaux. 
Trois jours après l'injection du mTHPC et de la forme pégylée à 0.15 mg/kg, aucune activité 
fluorescente n'a été détectée. Cependant, à 0.5 mg/kg, la fluorescence microscopique révèle une 
distribution hétérogène des deux photo-sensibilisateurs dans le tissu tumoral avec une accumulation 
prédominante dans les régions peri-vasculaires. Les deux médicaments montrent une distribution intra-
cellulaire homogène dans le cytoplasme et une absence de signalement dans le nucleus. 
La mesure de l'intensité fluorescente du mTHPC à 0.5mg/kg ne montre pas de différence significative 
entre le tissu tumoral et la région contrôle. Par contre, le PEG-mTHPC montre une intensité 
fluorescente supérieure dans le tissu tumoral que dans la peau (ratio tumeur- peau 0.94 pour le 
mTHPC et 1.73 pour le PEG-mTHPC). 
Conclusion 
L'utilisation du mTHPC à 0.15mg/kg induit une nécrose tumorale similaire à celle du PEG-mTHPC à 
dose équimolaire. Cependant, ce dernier démontre une photo-toxicité plus atténuée de la peau. La 
fluorescence microscopique permet de localiser les deux sensibilisateurs dans les différents 
compartiments tissulaires à partir d'une dose de 0.5 mg/kg. 
Le PEG-mTHPC induit un signalement fluorescent supérieur dans le tissu tumoral par rapport à la 
peau. 
La mesure du signalement fluorescent a le potentiel de prédire l'activité photodynamique du mTHPC 
et de sa forme pégylée dans les xénogreffes de mésothéliome humain dans un modèle de souris nue. 
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Background/Objectives: Correlation of photodynamic 
activity (PDT) and fluorescence signaling for free and 
pegylated meta-tetrahydroxyphenylchlorin (mTHPC) in 
nude mice with mesothelioma xenografts. 
Study Design/Materials and Methods: Twelve animais 
received light delivery (20 J/cm2 , 150 mW/cm2 , spot size 
1.2 cm) on the tumor and the hind leg 3 days after 
sensitization with O. 15 mg/kg free mTHPC (n = 6) or 
equimolar-dosed pegylated mTHPC (n = 6). Groups ofthree 
animais each were sensitized with O. 15 and 0.5 mg/kg free 
mTHPC or equimolar dosed pegylated mTHPC followed 
after 8 days by fluorescence microscopy measurements. 
Results: Pegylated mTHPC resulted in a similar extent of 
PDT-related tumor necrosis but in lower skin phototoxicity 
than free mTHPC. Both mTHPC formulations were 
heterogeneously distributed in the tumor and were mainly 
localized in perivascular are as. Pegylated mTHPC revealed 
a higher tumor to skin fluorescence intensity ratio than free 
mTHPC (P<0.001). 
Conclusions: Fluorescence signaling measurement has 
the potential to predict the photodynamic activity for both 
mTHPC formulations in mesothelioma xenografts. Lasers 
Surg. Med. 39:237-244, 2007. © 2007 Wiley-Liss, Inc. 
Key words: mTHPC Foscan; nude mice; animal model; 
tumor; skin phototoxicity; fluorescence microscopy; fluor-
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INTRODUCTION 
Following its advent more than two decades ago, 
photodynamic therapy (PDT) has emerged as a promising 
treatment modality for superficially growing tumors. The 
mechanism of action of PDT is based on the activation of a 
photosensitive drug by laser light of a specific wave 
length and selective destruction of tissues containing the 
sensitizer. Since the sensitizer is expected to accumulate 
preferentially in malignant tumors, PDT may lead to 
selective tumor destruction while sparing normal non-
affected tissues. However, the photosensitizers studied to 
date do not exclusively accumulate in malignancies as 
© 2007 Wiley-Liss, Inc. 
normal tissue also present some uptake. This has led to 
relevant morbidity after PDT of the chest cavity after 
surgery for pleural mesothelioma [1-6], even in the 
presence of new second generation sensitizers [7-13]. 
Sever al experimental studies focusing on PDT for mesothe-
lioma have shown that enhanced tumor selectivity may be 
obtained by modulating treatment conditions [14-18] and 
by pegylation of the sensitizer [19,20]. 
The current study compares the photodynamic activity, 
phototoxicity, and sensitizer distribution in tumors and 
skin for free and pegylated meta-tetrahydroxyphenyl-
chlorin (mTHPC) in nude mice with mesothelioma 
xenografts. Since previous work has shown that tissue 
concentration measurements offree and pegylated mTHPC 
performed by HPLC were of limited use for predicting the 
photodynamic activity in this model [15,19], we hypothe-
sized that fluorescence signaling measurements by fluor-
escence microscopy might be well suited in this respect. 
Fluorescence signaling of free and pegylated mTHPC was 
analyzed in tumors and skin by use of fluorescence 
microscopy in order to assess the photosensitizer distribu-
tion in tumors and to measure the tumor to skin 
fluorescence intensity ratio for both mTHPC formulations. 
MATERIALS AND METHODS 
Study Design 
The study design is summarized in Table 1. Free mTHPC 
and equimolar dosed pegylated mTHPC were compared 
with respect to photodynamic activity, phototoxicity 
and drug distribution within tumors and skin of 
nude mice bearing mesothelioma xenografts 3 days after 
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TABLE 1. Study Design 
Assessment of tumor necrosis 
and normal tissue damage 
Assessment by 
fluorescence microscopy 
Drug dose #Animals Drug dose #Animals 
Free mTHPC 0.15 mg/kg 6 0.15 mg/kg 3 
0.5 mg/kg 3 
Pegylated mTHPC 0.15 mg/kg 6 0.15 mg/kg 3 
Non-sensitized, non irradiated 
i.v. photosensitizer administration. Six tumor-bearing 
animals were given 0.15 mg/kg of free mTHPC and six 
were given an equimolar dose ofpegylated mTHPC. Three 
days later, all 12 animals received laser light on the tumor 
and an equally sized area on the hind leg at a drug-light 
interval (i.e., time interval between sensitizer administra-
tion and light delivery) of 3 days, followed by photo-
documentation and histological assessment of the 
treated areas 72 hours after photoirradiation. Another 
12 tumor-bearing animals were given photosensitizer. Of 
these 12 animals, 3 were given 0.15 mg/kg free mTHPC, 
3 were given an equimolar dose of pegylated mTHPC, 
3 were given 0.5 mg/kg free mTHPC, and 3 were given an 
equimolar dose ofpegylated mTHPC. This was followed by 
fluorescence microscopie assessment of the photosensitizer 
distribution within tumors and skin 3 days after drug 
administration. Six tumor-bearing animals that did not 
receive drug and were not photo-irradiated served as 
controls. 
Animais and Housing 
Specific Pathogen-free female nude mice (cdlnu/nu mice, 
Charles River Wiga, Sulzfeld, Germany), 6 to 8 weeks old at 
tumor implantation, were used. They were kept in auto-
claved cages in a laminar-air-fiow bench at 25 ± 2°C and 
55 ± 5% relative humidityunder artificial lightin a 12-hour 
rhythm. The animals were cared for in accordance with the 
established guidelines of the Local Ethical Committee on 
Animal Care of the University of Lausanne. 
Generation of Human Mesothelioma Xenografts 
Tumor transplantation was performed in animals under 
general anesthesia with Narketan (100 mg/kg i.p) and 
Xylapan (5 mg/kg i.p.) (Chassot AG, Bern, Switzerland). 
Usingthe trocar technique, fragments ofhuman malignant 
mesothelioma (H-meso-1, Mason, Worchester, MA) [21], 
based on a human mesothelioma cell suspension, were 
implanted subcutaneously behind the left omoplate of 
the nude mice as previously described [15]. At least three 
passages on nude mice were performed by the trocar 
technique after thawing from liquid nitrogen before 
treatment was initiated [20]. Experiments were performed 
on 30 animais at a tumor size of 8 mm diameter. 
Photosensitizer Administration 
Free mTHPC (Foscan'"') and pegylated mTHPC were 
kindly provided by Scotia Pharmaceuticals (Guildford, 
0.5 mg/kg 3 
3 3 
UK). mTHPC was dissolved in a pharmaceutical-grade 
solution of 40% ethanol and 60% propylene glycol for 
administration [15]. Pegylated mTHPC is a tetrakis-
(m-methoxypolyethylene glycol) derivative of 7,8-dihydro-
5,10,15,20-tetrakis(3-hydroxyphenyl)-21-23-[H]-por-
phyrin with a molecular weight of approximately 6,300 Da 
and results from the addition of four polyethylene glycol 
chains with a length of 2000 by use of triazine moieties to 
native mTHPC [19]. Pegylated mTHPC was dissolved in 
sterile 0.9% NaCl for administration [19,20]. 
Nine animais received 0.15 mg/kg free mTHPC and 
another nine animais received an equimolar dose of 
pegylated mTHPC. Three animais received 0.5 mg/kg and 
three an equimolar dose of pegylated mTHPC. Both 
sensitizer formulations were in,iected intravenously into 
the tail vein of the animais under general anesthesia and a 
volume ofO. l ml/10 g body weight of drug solution was used 
for injection. 
Photo irradiation 
Illumination was performed under general anesthesia 
with Narketan (100 mg/kg i.p) and Xylapan (5 mg/kg i.p.) 
(Chassot AG). The mice were positioned on a warm pad 
during light application. A diode laser emitting at 652 nm 
(Applied Optronics, South Plainfield, NJ) was connected by 
an SMA 905 connector to an optical quartz fiber (600 nm) 
containing a Jens (Medlight, Ecublens, Switzerland). 
In each animal, non-contact surface irradiation was 
performed on the tumor (through the intact skin overlying 
the tumor) and on an equal size area of the hind leg [15]. 
The irradiated spots were 1.2 cm in diameter and the 
treated surfaces were situated perpendicular to the 
incident laser beam. The power at the end of the fiber was 
measured by a power meter calibrated for 652 nm. The 
fiuence rate and fiuence on the treated surfaces was 
150 mW/cm2 and 20 J/cm2 , respectively. The exposure time 
of 133 seconds was controlled by a time shutter. 
Assessment of Photodynamic Activity on 
Tumors and Normal Tissue 
The treated areas were inspected and photo-documented 
on day 1, day 2, and day 3 after illumination. Seventy-two 
hours after illumination, the animals were sacrificed by an 
overdose of ether and were fixed in buffered formalin ( 10%). 
The irradiated are as of the tumor and the hind leg were eut 
at right angles to the surface from the center to the 
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periphery and were H&E-stained. The extent of tumor 
necrosis was determined by planimetry to better assess the 
inhomogeneous necrosis in a nodular tumor as previously 
described [15]. A transparent grid with 1 mm spacing was 
placed over the histological section taken through the 
largest diameter of the tumor and the number of grid 
intersections falling within the necrotic or non-necrotic 
tumor area was counted with the aid of a dissecting 
microscope. This procedure was repeated three times at 
different angles and the median value was used for 
subsequent statistical analysis. The extent of normal tissue 
damage (skin and underlying muscle of hind leg) was 
measured in mm with a dissecting microscope fitted with an 
eyepiece graticule. The pathologist (HJA) was blinded to 
the treatment conditions. 
Fluorescence Microscopie Assessment of 
Sensitizer Distribution in Tumors and Skin 
Twelve sensitized (free mTHPC = 6, pegy lated mTHPC = 
6) but non-irradiated animais were sacrificed by an over-
dose of ether 72 hours after i.v. administration. The tumors 
together with the overlying skin were harvested, frozen in 
liquid nitrogen with isopentane slush and stored at -70°C. 
Preparation of tissue slices and fluorescence microscopy 
measurements was performed as previously described [22]. 
Tissue sections were prepared in the dark to avoid 
photobleaching. The frozen tissue blocks were mounted in 
OCT medium (Tissue Tek II embedding compound, BDH 
Ltd, Poole, UK) and a series of sections was eut with a 
cryostat (Frigocut Model 2700, Reichert Ltd, Vienna, 
Austria). Six consecutive, non-stained, 5 ~lm thick tissue 
sections mounted on clean glass slides were prepared for 
each sample. From each frozen section, three images were 
recorded over three different parts of the slice to avoid 
photobleaching. We used a Zeiss AxioPlan-2 microscope 
equipped with a Zeiss Axiophot image analysis system 
and a filtered 100 W mercury lamp as an excitation 
light source. Images were recorded with a gray-scale 
camera with a 12-bits dynamic range and 2x2 binning, 
resulting in 694x 520 pixel images with 4,095 grey levels. A 
05 cube for epifluorescence (excitation BP395-440, Carl 
Zeiss, Jena, Germany) and a barrier filter (LP4 70 nm) were 
used. The photosensitizer's fluorescence was recorded 
using a second barrier filter (LP630 nm). The localization 
and specific intensity of the sensitizer's fluorescence were 
determined by subtracting the autofluorescence from 
the fluorescence image. For this purpose, a band pass 
D560/40 m filter was used (Chroma Tech, Brattleboro, VT). 
After recording the fluorescence images, the same slices 
were stained with H&E and compared with the fluores-
cence image from the same site in order to localize the 
sensitizer within the tissues. The relative fluorescence 
intensity emitted by the sensitizer was analyzed in the 
different areas oftumors and skin usingthe public domain 
program, NIH ImageJ 1.31 m (Bethesda, MD). The 
autofluorescence baclqp:ound subtraction procedure was 
performed using similar tissue samples from three non-
sensitized contrai animais. 
Statistical Analysis 
A non-parametric Kruskal-Wallis test was applied 
where appropriate. A bidirectional hypothesis was used 
and significance was accepted at aP<0.05. 
RESULTS 
PDT-Related Tumor Necrosis 
The extent of spontaneous tumor necrosis in 
non-sensitized, non-irradiated xenografts was 0.33 ± 
0.58 mm2• PDT with 0.15 mg/kg free mTHPC resulted in 
a tumor necrosis of 10 ± 5.4 mm2 and PDT with equimolar 
dosed pegylated mTHPC in 5.2 ± 4.6 mm2 . For both 
mTHPC formulations, the extent of tumor necrosis was 
significantly larger compared to control animals (P = 0.02). 
There was no significant difference in the extent of tumor 
necrosis between free mTHPC and pegylated mTHPC. 
PDT-Related Phototoxicity 
Inspection and photo-documentation of the treated areas 
on day 1, day 2, and day 3 after light delivery revealed a 
higher degree of skin alterations with a 0 .15 mg/kg dose of 
free mTHPC than with an equimolar dose of pegylated 
mTHPC. This holds true for both treatment sites in ail 
animais assessed (Figs 1 and 2). Histological assessment of 
the treated are as of the hind leg 3 days after light delivery 
revealed the absence ofnecrosis of the skin and underlying 
musculature for both mTHPC formulations on ail animals 
assessed. 
Fluorescence Signaling Assessment by 
Fluorescence Microscopy in Tumors and Skin 
No fluorescence signaling was detected 3 days after 
administration of 0.15 mg/kg free and an equimolar dose of 
pegylated mTHPC. Fluorescence microscopie assessment 
after administration ofü .5 mg/kg free and equimolar dose of 
pegylated mTHPC revealed a heterogeneous distribution 
for both mTHPC formulations in the tumors confined 
to perivascular areas (Figs 3 and 4). Centrally localized 
and non-vascularized tumor areas did not reveal fluores-
cence signaling for both mTHPC formulations. Both 
mTHPC formulations showed a homogenous intracellular 
distribution in the cytoplasm and absent signaling from the 
nuclei in areas with photosensitizer captation (Figs 3 
and4). 
Fluorescence intensity measurements revealed a mean 
autofluorescence background signaling of 57 ± 3 units for 
all tissues assessed. The recorded autofluorescence back-
ground was lower than the photosensitizer emission and 
comparable between different animals with respect to 
tumors and skin. Fluorescence intensity measurements 
3 days after receiving 0.5 mg/kg free mTHPC administra-
tion revealed no significant difference between tumor and 
skin (P = 0.2) with a ratio of tumor to skin fluorescence 
intensity of 0.94. Animais receiving an equimolar dose of 
pegylated mTHPC resulted in a higher fluorescence 
intensity in tumors than in skin (P<0.001) with a tumor 
to skin intensity ratio of 1. 73 (Fig. 5). 
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a 
b 
Fig. 1. PDT-related skin phototoxicity 3 days after photo-
irradiation with free mTHPC (0.15 mg/kg); (a) skin overlying 
the tumor; (b) skin overlying the hind leg. 
DISCUSSION 
PDT has emerged as a new treatment modality for 
superficially located tumors. It has also been investigated 
as an intraoperative adjunct following surgery in situations 
where a wide resection of tumor from otherwise healthy 
tissues is not feasible. This holds particularly true for 
malignant pleural mesothelioma. The tumor spreads along 
the pleural surfaces overlying the lung, the diaphragm, the 
chest wall , and the mediastinum and is characterized by a 
relentless local progression despite concerted treatment 
efforts including surgery, chemotherapy, and radiation 
[23-25]. Novel concepts for the treatment of mesothelioma 
have been investigated such as intraoperative PDT of the 
chest cavity following surgery, which has shown to be 
feasible and effective to a certain degree [26]. However, 
a 
b 
Fig. 2. PDT-related skin phototoxicity 3 clays after photo-
irracliation with equimolar dose of'pegylated mTHPC; (a) skin 
overlying the tumor; (b) skin overlying the hincl leg. 
intraoperative PDT for mesothelioma was associated with 
substantial morbidity under clinical conditions with a 
hematoporphyrin derivative photosensitizer. 
Efficacy and tumor selectivity of PDT depends on the 
photosensitizer, the treatment conditions, and the biologi-
cal and photophysical properties of the target tissues [27]. 
New sensitizers such as mTHPC were assessecl in order to 
optimize PDT for the treatment of mesothelioma. mTHPC 
has shown a powerful anti-tumor activity at relatively 
low drug and light doses and a fast reduction of skin 
photosensitivity in experimental and clinical settings. 
Additionally, the activation wavelength of 652 nm wave-
length light penetrates tissue deeply [8] . However, intra-
cavitary mTHPC-PDT of the chest cavity was associated 
with relevant side effects and normal tissue damage 
indicating poor selectivity under unfavorable treatment 
a 
c 
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b 
d 
Fig. 3. Fluorescence photomicrograph showing the loca lization of free mTHPC in mesothe-
lioma xenografts 3 days after i.v. administration (0.5 mg/kg); (a) heterogeneous photo-
scnsitizer distribution confined to perivascular areas and (b ) same slice after H&E sta ini ng 
(T = tumor, V = vessels) (original magnification 400 x ); (c) homogenous intracellular loca liza-
tion in the cytoplasm with absentsignaling from the nucleus in areas with sensit izer captation, 
and (d ) sa me sli ce after H&E staining (magnification 400 x ). 
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d 
Fig. 4. Fluorescence photomicrograph showing the loca lization of equimolar dosed pegylated 
mTHPC in mesothelioma xenografts 3 days after i.v. adminis tration; (a ) heterogeneous 
photosensitizer distribution confined to perivascul ar areas and (b) same slice after H&E 
staining (T = tumor, V = vessels) (original magnification 400 x ); (c) homogenous intracellular 
loca lization in the cytoplasm with absent signaling from tl1 e nucleus in areas with sens itizer 
captation, and (d ) same slice after H&E staining (magnification 400 x ). 
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• Free mTHP:: relative fluorescence intensity can be measured which 
~ pemoaled mTHPC allows an estimation of the sensitizer distribution in 
different tissues. 
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Fig. 5. Fluorescence intensity measurements 3 days after i.v. 
injection of free mTHPC (0.5 mg/kg) and an equimolar dose of 
pegylated mTHPC on the tumors and skin. 
conditions [9 - 11 ,13,17]. ln an attempt to increase poor 
selectivity of free mTHPC for tumor, macromolecular 
derivatives of mTHPC were arranged by linking hydroxyl 
(polyethylene glycol) chains of varying lengths to the 
photosensitizer (i.e., pegylation) [19 ,20]. Pegylation leads 
to increased water solubility of many drugs and increases 
plasma half life due to reduced kidney clearance and a 
decreased drug uptake by the reticuloendothelial system 
[28]. The prolonged drug circulation time and a better 
permeability of the tumor microvasculature for high 
molecular weight compounds are believed to enhance 
tumor drug uptake of pegylated compou nds [29]. 
Severa! studies have compared the photodynamic 
activity of free and pegylated mTHPC on human mesothe-
lioma xenografts [19,20,30] and have shown a similar 
extent oftumor necrosis but a lower degree of normal tissue 
damage with pegylated mTHPC when compared to an 
equimolar dose of free mTHPC. However, photosensitizer 
concentration in tissue measured by HPLC did not 
correlate with the photodynamic activity for both mTHPC 
formulations [15,19]. The difference in photodynamic 
activity for free and pegylated mTHPC may be related to 
a different spatial distribution of the photosensitizers 
in tumors and normal tissues which may not necessarily 
be detected by sensitizer concentration measurements. In 
contrast, fluorescence microscopy allows the localization 
of a photosensitizer in different tissue compartments by 
registration of the sensitizer's fluorescence signaling 
after activation. After recording the fluorescence images, 
the same slices are stained with H&E and compared with 
the fluorescence image from the same site in order to 
localize the sensitizer within the tissues. ln addition, the 
Our results revealed a similar photodynamic activity in 
mesothelioma xenografts but a lower skin phototoxicity 
with pegylated mTHPC compared to equimolar dosed free 
mTHPC at a drug-light interval of 3 days. The extent of 
PDT-related tumor necrosis was significantly higher for 
both mTHPC formulations than in non-treated tumors but 
there was no significant difference between free and 
pegylated mTHPC for the treatment conditions applied. 
These results are consistent with the findings of previous 
studies [20]. Fluorescence microscopie analysis revealed no 
detectable fluorescence signaling at a dose of 0.15 mg/kg 
free or equimolar dose of pegylated mTHPC, but a 
heterogeneous fluorescence signaling for both mTHPC 
formulations in tumors confined to perivascular areas 
was detected at a dose of 0.5 mg/kg free or equimolar dose 
of pegylated mTHPC. Similar results have been described 
by other investigators who assessed the distribution of 
free and pegylated mTHPC in human adenocarcinoma 
xenografts [301. The heterogeneous spatial distribution of 
free and pegylated mTHPC in xenografts may explain 
the findings of previous studies showing that for the 
same treatment conditions are applied, well-vascularized 
adenocarcinoma xenografts revealed a larger extent of 
mTHPC-PDT-related tumor necrosis than squamous cell 
carcinoma or mesothelioma xenogra fts which were poor in 
stroma and vessels [31,32]. Fluorescence intens ity mea-
surements after administration offree mTHPC (0.5 mg/kg) 
revealed no significant difference between tumor and skin 
whereas an equimolar dose of pegylated mTHPC resulted 
in significantly higher fluorescence intensity in tumors 
than in skin . Our results suggest that fluorescence 
intensity measurements may predict the photodynamic 
effect for both mTHPC formulations in tumors and skin 
but requires refinements in order to detect sensitizer 
fluorescence signaling at lower drug doses. 
In conclusion, pegylated mTHPC revealed similar photo-
dynamic activity but improved tumor selectivity versus 
free mTHPC. Fluorescence signaling measurements have 
the potential to predict the photodynamic activity for both 
mTHPC formulations. 
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